Clinical Trial Detail

NCT ID NCT02419755
Title Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors St. Jude Children's Research Hospital
Indications

hematologic cancer

Therapies

Cytarabine

Mercaptopurine

Methotrexate

Pegaspargase

Vorinostat

Doxorubicin

Bortezomib

Dexamethasone

Mitoxantrone

Prednisone

Age Groups: child

Additional content available in CKB BOOST